Clinical Trials Browser

Topotecan × Genitourinary × Clear all

Wilms Tumor

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00638898 2025-03-20

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Phase 1 Completed

25 enrolled

CNSGenitourinarySarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Testicular Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma

NCT02390843 2020-04-03

AflacST1402

Phase 1 Completed

13 enrolled

CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Carcinoma, Renal Cell, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Rhabdoid Tumor

NCT00158886 2017-11-14

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

Phase 1 Terminated

26 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00084565 2013-07-10

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00002515 2013-06-24

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

Phase 2 Completed

CNSGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmSarcoma

Testicular Germ Cell Tumor, Burkitt Lymphoma, Chondrosarcoma, Fibrosarcoma, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lymphoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Retinoblastoma, Sarcoma, Osteosarcoma, Testicular Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Dendritic Cell Sarcoma, Interdigitating, Desmoplastic Small Round Cell Tumor

NCT00187031 2008-06-04

A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor

Phase 2 Completed

37 enrolled

Genitourinary

Wilms Tumor

Clinical Trials

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

AflacST1402

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor